Katie B. Ryan

Dr. Katie B. Ryan

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
NVNavin Kumar Verma
Navin Kumar Verma
KCKieran Crosbie-Staunton
Kieran Crosbie-Staunton
ASAmro Satti
Amro Satti
SGShane Gallagher
Shane Gallagher
KRKatie B. Ryan
Katie B. Ryan
Yurii Gun'koYurii Gun'ko
Yurii Gun'ko
Aerosolized therapeutics hold great potential for effective treatment of various diseases including lung cancer. In this context, there is an urgent need to develop novel nanocarriers suitable for drug delivery by nebulization. To address this need, we synthesized and characterized a biocompatible drug delivery vehicle following surface coating of Fe3O4 magnetic nanoparticles (MNPs) with a polymer poly(lactic-co-glycolic acid) (PLGA). The polymeric shell of these engineered nanoparticles was loaded with a potential anti-cancer drug quercetin and their suitability for targeting lung cancer cells via nebulization was evaluated.

7 November 2015 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
CMCarol A. McCarthy
Carol A. McCarthy
RARobert J. Ahern
Robert J. Ahern
RDRakesh Dontireddy
Rakesh Dontireddy
KRKatie B. Ryan
Katie B. Ryan
ACAbina Crean
Abina Crean
Introduction: Silica materials, in particular mesoporous silicas, have demonstrated excellent properties to enhance the oral bioavailability of poorly water-soluble drugs. Current research in this ...

1 November 2013 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
RARobert J. Ahern
Robert J. Ahern
JHJohn P. Hanrahan
John P. Hanrahan
JTJoseph M. Tobin
Joseph M. Tobin
KRKatie B. Ryan
Katie B. Ryan
ACAbina Crean
Abina Crean

13 May 2022 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
RARasha A. Alshaikh
Rasha A. Alshaikh
CWChristian Waeber
Christian Waeber
KRKatie B. Ryan
Katie B. Ryan
There is an increasing momentum in research and pharmaceutical industry communities to design sustained, non-invasive delivery systems to treat chronic neovascular ocular diseases that affect the posterior segment of the eye including age-related macular degeneration and diabetic retinopathy. Current treatments include VEGF blockers, which have revolutionized the standard of care for patients, but their maximum therapeutic benefit is hampered by the need for recurrent and invasive administration procedures. Currently approved delivery systems intended to address these limitations exploit polymer technology to regulate drug release in a sustained manner. Here, we critically review sustained drug delivery approaches for the treatment of chronic neovascular diseases affecting the ocular posterior segment, with a special emphasis on novel and polymeric technologies spanning the spectrum of preclinical and clinical investigation, and those approved for treatment. The mechanism by which each formulation imparts sustained release, the impact of formulation characteristics on release and foreign body reaction, and special considerations related to the translation of these systems are discussed.

21 October 2011 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
PGPaul Galvin
Paul Galvin
Damien ThompsonDamien Thompson
Damien Thompson
KRKatie B. Ryan
Katie B. Ryan
AMAnna McCarthy
Anna McCarthy
AMAnne Moore
Anne Moore
Ronan MacLoughlinRonan MacLoughlin
Ronan MacLoughlin

25 January 2024 in Journal of Controlled Release
Verified
Journal Article
Open access
MNMichael T. Neary
Michael T. Neary
LMLianne M. Mulder
Lianne M. Mulder
PKPiotr S. Kowalski
Piotr S. Kowalski
RMRonan MacLoughlin
Ronan MacLoughlin
ACAbina M. Crean
Abina M. Crean
KRKatie B. Ryan
Katie B. Ryan
In the past decade RNA-based therapies such as small interfering RNA (siRNA) and messenger RNA (mRNA) have emerged as new and ground-breaking therapeutic agents for the treatment and prevention of many conditions from viral infection to cancer. Most clinically approved RNA therapies are parenterally administered which impacts patient compliance and adds to healthcare costs. Pulmonary administration via inhalation is a non-invasive means to deliver RNA and offers an attractive alternative to injection. Nebulisation is a particularly appealing method due to the capacity to deliver large RNA doses during tidal breathing. In this review, we discuss the unique physiological barriers presented by the lung to efficient nebulised RNA delivery and approaches adopted to circumvent this problem. Additionally, the different types of nebulisers are evaluated from the perspective of their suitability for RNA delivery. Furthermore, we discuss recent preclinical studies involving nebulisation of RNA and analysis in in vitro and in vivo settings. Several studies have also demonstrated the importance of an effective delivery vector in RNA nebulisation therefore we assess the variety of lipid, polymeric and hybrid-based delivery systems utilised to date. We also consider the outlook for nebulised RNA medicinal products and the hurdles which must be overcome for successful clinical translation. In summary, nebulised RNA delivery has demonstrated promising potential for the treatment of several lung-related conditions such as asthma, COPD and cystic fibrosis, to which the mode of delivery is of crucial importance for clinical success.